4-(3-甲基苯氧基)苯甲酸 | 62507-85-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(3-甲基苯氧基)苯甲酸
• 英文名称: 4-(3-methylphenoxy)benzoic acid
• CAS: 62507-85-1
• 化学式: C₁₄H₁₂O₃
• mdl: MFCD02068131
• 分子量: 228.247
• InChiKey: XBZMSARMROSBTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-(3-甲基苯氧基)苯甲酸 在 四溴化碳 、 四丁基氟化铵 、 1-羟基苯并三唑 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist

  摘要：

  S1P(3)-sparing S1P(1) agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC50 value of 4.0 nM for human S1P(1) and over 5000-fold selectivity against S1P(3). The in vivo immunosuppressive efficacy was evaluated in rats on host versus graft reaction and the ID50 value was determined at 0.407 mg/kg. The docking studies of CS-2100 with the homology model of S1P(1) and S1P(3) showed that the ethyl group on the thiophene ring of CS-2100 was sterically hindered by Phe263 in S1P(3), not in the case of Leu276 in S1P(1). This observation gives an explanation for the excellent S1P(3)-sparing characteristic of CS-2100. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.019
• 作为产物：
  描述：

  methyl 4-(3'-methylphenoxy)benzoate 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 4-(3-甲基苯氧基)苯甲酸
  参考文献：
  名称：

  高效N-酰基乙醇胺酸酰胺酶（NAAA）抑制剂的鉴定：恶唑烷酮衍生物的末端苯基部分的优化

  摘要：

  ñ-酰基乙醇胺酸酰胺酶（NAAA）是半胱氨酸水解酶，参与脂肪酸乙醇酰胺（如棕榈酰乙醇酰胺（PEA））的失活。NAAA抑制可为治疗需要更高PEA水平的疾病提供潜在的治疗策略。在本研究中，我们报道了恶唑烷酮衍生物作为NAAA抑制剂的结构-活性关系（SAR）研究。研究了恶唑烷酮衍生物的末端苯环的一系列取代基或烷基取代基。结果表明，这些恶唑烷酮衍生物对NAAA的抑制能力取决于末端基团的大小，柔韧性和亲脂性。SAR结果表明，较小的亲脂性3-苯基取代基或含羟基的4-苯基取代基对于获得最佳效价是优选的。此外，出于高抑制效力，也优选远端脂肪族替代物。快速稀释和动力学分析表明，具有不同末端苯基部分的恶唑烷酮衍生物通过不同的机理抑制NAAA。这项研究确定了几种高效的NAAA抑制剂，包括1a（F215，IC 50  = 0.009μM ），1o（IC 50  = 0.061μM）和2e（IC 50  = 0.0

  DOI：

  10.1016/j.ejmech.2017.08.004

文献信息

• Syntheses and antimicrobial activities of ogipeptin derivatives
  作者：Shingo Takiguchi、Hidehito Homma、Tetsunori Fujisawa、Yuki Hirota-Takahata、Yasunori Ono、Masaaki Kizuka、Yuki Ishii、Satomichi Yoshimura、Takahide Nishi

  DOI：10.1016/j.bmcl.2021.128093

  日期：2021.6

  Novel cyclic peptide derivatives based on ogipeptins A, B, C, and D were synthesized. Starting with a mixture of ogipeptins A–D, a practical four-step synthetic procedure was followed to prepare novel derivatives with various kinds of acyl side chains. Among the 45 new synthetic derivatives identified, the antibacterial activities of compounds 8-3 and 8-38 were comparable with those of ogipeptin A

  合成了基于 ogipeptins A、B、C 和 D 的新型环肽衍生物。从 ogipeptins A-D 的混合物开始，遵循实用的四步合成程序来制备具有各种酰基侧链的新型衍生物。中标识的45个新的合成衍生物，化合物的抗菌活性8-3和8-38分别与ogipeptin A的可比较的在体外肾毒性使用LLC-PK1细胞的筛选中，化合物8-3和8-38显示显著下细胞毒性 (LD 20 > 480 μM) 高于粘菌素 (LD 20 = 44.2 μM)。
• 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS
  申请人：RESEARCH TRIANGLE INSTITUTE

  公开号：US20150005315A1

  公开（公告）日：2015-01-01

  Provided are compounds represented by the formula: where R, Y 3 , R 1 , R 2 , R 3 , R 4 , R 6 , G, R 7 , E 1 , E 2 , A, B, W, X, Y and Z are as defined herein.

  提供的化合物由以下公式表示：其中R，Y3，R1，R2，R3，R4，R6，G，R7，E1，E2，A，B，W，X，Y和Z的定义如下。
• Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors
  作者：Emanuele Marco Gargano、Enrico Perspicace、Angelo Carotti、Sandrine Marchais-Oberwinkler、Rolf W. Hartmann

  DOI：10.1016/j.bmcl.2015.11.047

  日期：2016.1

  Four different classes of new 17 beta-hydroxysteroid dehydrogenase type 2 (17 beta-HSD2) inhibitors were synthesized, in order to lower the cytotoxicity exhibited by the lead compound A, via disrupting the linearity and the aromaticity of the biphenyl moiety. Compounds 3, 4, 7a and 8 displayed comparable or better inhibitory activity and selectivity, as well as a lower cytotoxic effect, compared to the reference compound A. The best compound 4 (IC50 = 160 nM, selectivity factor = 168, LD50 approximate to 25 mu M) turned out as new lead compound for inhibition of 17 beta-HSD2. (C) 2015 Elsevier Ltd. All rights reserved.
• Discovery of <i>N</i>-{4-[(3-Hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide Analogues as Selective Kappa Opioid Receptor Antagonists
  作者：Chad M. Kormos、Chunyang Jin、Juan Pablo Cueva、Scott P. Runyon、James B. Thomas、Lawrence E. Brieaddy、S. Wayne Mascarella、Hernán A. Navarro、Brian P. Gilmour、F. Ivy Carroll

  DOI：10.1021/jm400275h

  日期：2013.6.13

  There is continuing interest in the discovery and development of new kappa opioid receptor antagonists. We recently reported that N-substituted 3-methyl-4-(3-hydroxyphenyl)piperazines were a new class of opioid receptor antagonists. In this study, we report the syntheses of two piperazine JDTic-like analogues. Evaluation of the two compounds in an in vitro [S-35]GTP gamma S binding assay showed that neither compound showed the high potency and kappa opioid receptor selectivity of JDTic. A library of compounds using the core scaffold 21 was synthesized and tested for their ability to inhibit [S-35]GTP gamma S binding stimulated by the selective kappa opioid agonist U69,593. These studies led to N-[(1S)-1-[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyll-2-methylpropyl]-4-phenoxybenzamide (11a), a compound that showed good kappa opioid receptor antagonist properties. An SAR study based on 11a provided 28 novel analogues. Evaluation of these 28 compounds in the [S-35]GTP gamma S binding assay showed that several of the analogues were potent and selective kappa opioid receptor antagonists.
• Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2
  作者：Christopher G. Nasveschuk、Alexandre Gagnon、Shivani Garapaty-Rao、Srividya Balasubramanian、Robert Campbell、Christina Lee、Feng Zhao、Louise Bergeron、Richard Cummings、Patrick Trojer、James E. Audia、Brian K. Albrecht、Jean-Christophe P. Harmange

  DOI：10.1021/ml400494b

  日期：2014.4.10

  The identification and development of a novel series of small molecule Enhancer of Zeste Homologue 2 (EZH2) inhibitors is described. A concise and modular synthesis enabled the rapid development of structure activity relationships, which led to the identification of 44 as a potent, SAM-competitive inhibitor of EZH2 that dose-dependently decreased global H3K27me3 in KARPAS-422 lymphoma cells.